Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The investment firm Blackstone Life Sciences will provide the RNA interference (RNAi) company Alnylam Pharmaceuticals with up to $2 billion. Half will be in exchange for up to 50% of the royalties Alnylam will receive if its cholesterol-lowering RNAi therapy, inclisiran, is approved. Alnylam licensed inclisiran to The Medicines Company in 2013, and Novartis bought that firm for $9.7 billion in January. Blackstone will also purchase $100 million worth of Alnylam’s stock, provide up to $150 million to develop two additional cardiometabolic RNAi programs, and provide a loan of up to$750 million.
This article has been sent to the following recipient: